Santhera Pharmaceuticals Holding AG
SANN
Clasificación en acciones
#16590
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Precio por acción
$17.23
Capitalización bursátil
$263.68M
Cambio (1 día)
-4.18%
Cambio (1 año)
38.54%
País
CH
Comercio Santhera Pharmaceuticals Holding AG (SANN)
Categoría
Healthcare
Historial del precio de la acción de Santhera Pharmaceuticals Holding AG (SANN)
Precio más alto de cierre: $18.92 el 2026-10-01
Precio más bajo de cierre: $44.13 el 2014-03-01
Precio más bajo de cierre: $44.13 el 2014-03-01
Historial del precio de la acción de Santhera Pharmaceuticals Holding AG desde 2014 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | 22.24% |
| 2025 | 42.98% |
| 2024 | -6.16% |
| 2023 | 41.12% |
| 2022 | -43.82% |
| 2021 | -53.14% |
| 2020 | -74.39% |
| 2019 | -17.31% |
| 2018 | -49.89% |
| 2017 | -38.99% |
| 2016 | -48.52% |
| 2015 | -16.32% |
| 2014 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $537.25 | 25.98% |
US
|
|
| $195.62 | 628.57% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $881.90 | 8.32% |
NL
|
